Sitagliptin & Metformin Tablets 50/500 Mg

Sitagliptin & Metformin Tablets 50/500 Mg

Sitagliptin & Metformin Tablets 50/500 Mg is a combination oral anti-diabetic medication used for the management of type 2 diabetes mellitus. It combines sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide), offering dual action to control blood sugar levels effectively. This combination helps improve insulin secretion, reduce glucose production, and enhance insulin sensitivity. It is commonly prescribed when single-drug therapy is not sufficient. In diabetes care, individual therapies like Sitagliptin Tablets 50 Mg and insulin options such as Tresiba Flextouch Pen are also used depending on patient needs.

Mechanism of Action

Dual Action Therapy

• Sitagliptin increases incretin hormone levels, enhancing insulin release.
• Metformin reduces glucose production in the liver and improves insulin sensitivity.

Improved Glycemic Control

Together, they provide better control of both fasting and post-meal blood sugar levels. For clinical insights, refer to American Diabetes Association (ADA) and for safety guidance, consult Mayo Clinic – Sitagliptin and Metformin Information.

Medical Uses

Sitagliptin & Metformin Tablets 50/500 Mg is used for:

• Type 2 diabetes mellitus
• Blood sugar control
• Combination therapy for improved glycemic management

It is widely used in patients requiring dual therapy.

Dosage and Administration

This medication is usually taken with meals to reduce gastrointestinal side effects, as directed by a healthcare provider. The dosage may be adjusted based on blood sugar levels and patient response. In clinical practice, Sitagliptin Tablets 50 Mg may be used as monotherapy, while Tresiba Flextouch Pen is used when insulin therapy is required.

Clinical Effectiveness

Clinical studies show that this combination effectively lowers blood sugar levels, improves insulin function, and reduces the risk of diabetes-related complications when used consistently.

Safety and Side Effects

Common Side Effects

• Nausea
• Diarrhea
• Headache

Serious Risks

• Lactic acidosis (rare)
• Pancreatitis (rare)

Regular monitoring is recommended. For more details, refer to Mayo Clinic – Sitagliptin and Metformin Information.

Contraindications and Precautions

This medication should not be used in:

• Patients with severe kidney disease
• Individuals with metabolic acidosis
• Patients with a history of pancreatitis (use with caution)

Consult a healthcare provider before use.

Drug Interactions

It may interact with other antidiabetic medications, increasing the risk of hypoglycemia. Patients should inform their healthcare provider about all medicines they are taking. For further reading, refer to American Diabetes Association (ADA).

FAQs